ASX-listed health technology company Volpara Health Technologies Ltd (ASX: VHT) this morning provided a trading update to investors.
In an announcement to the ASX, the small-cap company said its annual recurring revenue (ARR) is now $NZ2.6 million, up strongly on the prior year. Total Contract Value (TCV) signed during the third quarter stood at $NZ2.4 million, up 5%, at 15 December.
“These figures demonstrate that this has been a great quarter, and we still have two strong
weeks of US sales activity ahead,” CEO Dr Ralph Highnam said.
“This quarter we have grown sales and seen increased deal flow, while keeping costs flat compared to last year, proving that we have a scalable, sticky product that is being well received in the US market, where we have first-mover advantages.”
Volpara is a New Zealand-based health technology company which was founded in 2009. The company develops digital solutions for breast cancer screening, helping to identify women who have a high risk of developing breast cancer.
